Bottom line
What does LYFCX hold?
LYFCX held 62 positions as of Jun 30, 2026. Its largest holding is Gilead Sciences Inc at 5.53% of the fund, and the top 10 positions add up to 40.7%. By asset type it is 96% stocks, 4% cash & short-term funds.
Updated Aug 27, 2026
LYFCX top 25 holdings
| # | Holding | Type | % of fund | Value |
|---|---|---|---|---|
| 1 | Gilead Sciences Inc GILEAD SCIENCES |
Stocks | 5.53% | $2.6M |
| 2 | Vertex Pharmaceuticals Inc VERTEX PHARM |
Stocks | 5.33% | $2.5M |
| 3 | Astrazeneca Plc | Stocks | 4.63% | $2.2M |
| 4 | First American Funds Inc FIRST AM-TR OB-X |
Cash & short-term funds | 4.26% | $2.0M |
| 5 | Roivant Sciences Ltd ROIVANT SCIENCES |
Stocks | 3.67% | $1.7M |
| 6 | Argenx Se ARGENX SE - ADR |
Stocks | 3.59% | $1.7M |
| 7 | Neurocrine Biosciences Inc NEUROCRINE BIOSC |
Stocks | 3.51% | $1.6M |
| 8 | Incyte Corp | Stocks | 3.51% | $1.6M |
| 9 | Axsome Therapeutics Inc AXSOME THERAPEUT |
Stocks | 3.43% | $1.6M |
| 10 | Apogee Therapeutics Inc APOGEE THERAPEUT |
Stocks | 3.28% | $1.5M |
| 11 | Ionis Pharmaceuticals Inc IONIS PHARMACEUT |
Stocks | 2.62% | $1.2M |
| 12 | Ascendis Pharma A/s ASCENDIS PHARMA |
Stocks | 2.62% | $1.2M |
| 13 | Insmed Inc | Stocks | 2.60% | $1.2M |
| 14 | Protagonist Therapeutics Inc PROTAGONIST THER |
Stocks | 2.41% | $1.1M |
| 15 | Personalis Inc | Stocks | 2.27% | $1.1M |
| 16 | Rhythm Pharmaceuticals Inc RHYTHM PHARMACEU |
Stocks | 2.25% | $1.0M |
| 17 | Abbvie Inc | Stocks | 1.95% | $909.2K |
| 18 | Jazz Pharmaceuticals Plc JAZZ PHARMACEUTI |
Stocks | 1.87% | $870.6K |
| 19 | Amgen Inc | Stocks | 1.83% | $855.3K |
| 20 | Biogen Inc | Stocks | 1.80% | $840.7K |
| 21 | Catalyst Pharmaceuticals Inc CATALYST PHARMAC |
Stocks | 1.59% | $742.4K |
| 22 | Halozyme Therapeutics Inc HALOZYME THERAPE |
Stocks | 1.58% | $737.8K |
| 23 | Meiragtx Holdings Plc MEIRAGTX HOLDING |
Stocks | 1.58% | $735.9K |
| 24 | Krystal Biotech Inc KRYSTAL BIOTECH |
Stocks | 1.55% | $722.9K |
| 25 | Nuvalent Inc NUVALENT INC-A |
Stocks | 1.47% | $686.4K |
Source: SEC Form N-PORT, period ended Jun 30, 2026, filed Aug 27, 2026